On 22 March, brand identification company Avery Dennison Corporation (NYSE: AVY) announced plans to acquire Paxar Corporation for $1.34 billion, approximately $30.50 per share. This price represents a 27% premium over Paxar's close at $24.03 on the day the proposed acquisition was announced. Paxar Corporation (NYSE: PXR) recently announced it has delayed its annual meeting from 3 May to some time in either June or July in order to allow more time for its board to consider Avery's offer.

Anyone who has ever run address labels through a printer is familiar with Avery Dennison. But the company is more than just a label maker. Its Retail Information Services (RIS) division provides supply chain solutions, data management systems, as well as shipping and tracking. Currently, Avery is a $5 billion a year company. It has operations in 49 countries. Paxar is also a supply chain management company, primarily to the retail and apparel industries worldwide, particularly in Europe. The proposed acquisition of Paxar by Avery Dennison will lead, according to Avery's board, to $90-100 million in cost savings. Before that can happen, however, Avery predicts integration costs in excess of $125 million, primarily to merge the two IT systems. Avery management claims the acquisition will generate lower production costs, higher quality, and quicker delivery. I guess we wait until the summer to find out the next step.

Avery Dennison closed yesterday at $64.07, down $0.20. Paxar stock closed yesterday at $28.65, up $0.03 for the day.

MOST NOTEWORTHY: Vonage Holdings Corp (VG), Boston Scientific Corp (BSX), Sunoco, Inc (SUN) and CV Therapeutics, Inc (CVTX) were some of today's more notable downgrades:

• Vonage Holdings Corp (NYSEL VG) was downgraded to Underperform from Peer Perform at Bear Stearns following the court injunction barring Vonage from using Verizon Communications' (VZ) patented technology.

• Boston Scientific Corp (NYSE: BSX) was cut to Market Perform from Outperform at BMO. Cowen removed Boston Scientific from its Focus List citing superior clinical results from Abbott Laboratories' (ABT) drug-eluting stent, Xience V.

• Deutsche Bank downgraded Sunoco (NYSE: SUN) to Hold from Buy with a $72 target on valuation.

• CV Therapeutics (NASDAQ: CVTX) was downgraded at Deutsche Bank, to Sell from Hold with a $2 target. The downgrade was ahead of the full Ranexa Merlin PIII data to be presented at the American College of Cardiology on Tuesday, March 27th, as the firm believes it will fall short of generating sufficient positive data trends for supporting Ranexa's outlook.

OTHER DOWNGRADES:

• DaimlerChrysler (NYSE: DCX) was removed from JP Morgan's Focus List as the firm believes the potential divestiture of Chrysler is at least partially priced into shares; JP Morgan maintains an Overweight rating on the stock.

• Morgan Stanley cut Progressive Corp (NYSE: PGR) to Underweight from Equal-Weight.

• William Blair downgraded Kronos Inc (NASDAQ: KRON) to Market Perform from Outperform following the company's acquisition.

• Bank of America downgraded Paxar Corp (NYSE: PXR) to Neutral from Buy on news of Avery Dennison Corp's (AVY) acquisition of the company.

• Deutsche Bank cut Tesoro Corp (NYSE: TSO) to Sell from Hold with an $85 target.

• Goldman Sachs cut Volvo (NASDAQ: VOLV) to Neutral from Buy on valuation.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).